Therapie des differenzierten
Schilddrüsenkarzinoms

C Hubold; I Buchmann; H Lehnert

doi:10.1055/s-0031-1275823

DMW - Deutsche Medizinische Wochenschrift, Table of Contents

Dtsch Med Wochenschr 2011; 136(17): 891-895
DOI: 10.1055/s-0031-1275823

Aktuelle Diagnostik & Therapie | Review article

Endokrinologie, Onkologie
© Georg Thieme Verlag KG Stuttgart · New York

Therapie des differenzierten Schilddrüsenkarzinoms

The treatment of differentiated thyroid cancerC. Hubold¹ , I. Buchmann² , H. Lehnert¹

¹ Medizinische Klinik 1, UKSH Campus Lübeck
² Klinik für Radiologie und Nuklearmedizin, UKSH Campus Lübeck

Abstract

Schlüsselwörter

Schilddrüsenkarzinom - Radiojodtherapie - Thyreoidektomie - Zytostatika - Proteinkinaseinhibitoren - Leitlinien

Keywords

thyroid neoplasm - iodine radioisotopes - thyroidectomy - antineoplastic agents - protein kinase inhibitors - guidelines for practice

Full Text

References

Literatur

1 TNM Classification of Malignant Tumours, 6th edition. New York: Wiley-Liss; 2002
2 WHO histological classification of thyroid and parathyroid tumours. In: Delmas P, Locati LD, Heracek J, Eng C, editors World Health Organization Classification of Tumours. Pathology & Genetics. Tumours of Endocrine Organs. Lyon: IARC Press; 2004: 29-123
3 Brabant G. Thyrotropin suppressive therapy in thyroid carcinoma: what are the targets?. J Clin Endocrinol Metab. 2008; 93 1167-1169
4 Cooper D S, Doherty G M, Haugen B R. et al . Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009; 19 1167-1214
5 Dralle H, Karges W, Reiners C, Schmid K W. Maligne Schilddrüsentumoren. In: Lehnert H, Rationelle Diagnostik und Therapie in Endokrinologie, Diabetologie und Stoffwechsel. Stuttgart, New York: Georg Thieme Verlag; 2009: 95-112
6 Dralle H, Lorenz K, Machens A, Nguyen T P. [Thyroid carcinoma found incidentally after thyroidectomy: postoperative strategy. Dtsch Med Wochenschr. 2009; 134 2517-2520
7 Dralle H, Machens A. Surgical approaches in thyroid cancer and lymph-node metastases. Best Pract Res Clin Endocrinol Metab. 2008; 22 971-987
8 Ford D, Giridharan S, McConkey C. et al . External beam radiotherapy in the management of differentiated thyroid cancer. Clin Oncol (R Coll Radiol ). 2003; 15 337-341
9 Frates M C, Benson C B, Charboneau J W. et al . Management of thyroid nodules detected at US: Society of Radiologists in Ultrasound consensus conference statement. Radiology. 2005; 237 794-800
10 Gottlieb J A, Hill Jr C S. Chemotherapy of thyroid cancer with adriamycin. Experience with 30 patients. N Engl J Med. 1974; 290 193-197
11 Hackshaw A, Harmer C, Mallick U, Haq M, Franklyn J A. 131I activity for remnant ablation in patients with differentiated thyroid cancer: A systematic review. J Clin Endocrinol Metab. 2007; 92 28-38
12 Harach H R, Franssila K O, Wasenius V M. Occult papillary carcinoma of the thyroid. A „normal” finding in Finland. A systematic autopsy study. Cancer. 1985; 56 531-538
13 Husmann G, Kaatsch P, Katalinic A. et al .Beiträge zur Gesundheitsberichterstattung des Bundes Krebs in Deutschland 2005/2006 – Häufigkeiten und Trends. 7. Ausgabe ed. Berlin: Robert Koch-Institut, Gesellschaft der epidemiologischen Krebsregister in Deutschland e. V.; 2010
14 Jonklaas J, Sarlis N J, Litofsky D. et al . Outcomes of patients with differentiated thyroid carcinoma following initial therapy. Thyroid. 2006; 16 1229-1242
15 Kloos R T, Ringel M D, Knopp M V. et al . Phase II trial of sorafenib in metastatic thyroid cancer. J Clin Oncol. 2009; 27 1675-1684
16 Luster M, Clarke S E, Dietlein M. et al . Guidelines for radioiodine therapy of differentiated thyroid cancer. Eur J Nucl Med Mol Imaging. 2008; 35 1941-1959
17 Maenpaa H O, Heikkonen J, Vaalavirta L, Tenhunen M, Joensuu H. Low vs. high radioiodine activity to ablate the thyroid after thyroidectomy for cancer: a randomized study. PLoS One. 2008; 3 e1885
18 McGriff N J, Csako G, Gourgiotis L, Lori C G, Pucino F, Sarlis N J. Effects of thyroid hormone suppression therapy on adverse clinical outcomes in thyroid cancer. Ann Med. 2002; 34 554-564
19 Nikiforov Y E, Steward D L, Robinson-Smith T M. et al . Molecular testing for mutations in improving the fine-needle aspiration diagnosis of thyroid nodules. J Clin Endocrinol Metab. 2009; 94 2092-2098
20 Pacini F, Schlumberger M, Dralle H, Elisei R, Smit J W, Wiersinga W. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol. 2006; 154 787-803
21 Pacini F, Ladenson P W, Schlumberger M, Driedger A, Luster M, Kloos R T. et al . Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: results of an international, randomized, controlled study. J Clin Endocrinol Metab. 2006; 91 926-932
22 Schmid K W. Knoten in der Schilddrüse – histologische und zytologische Diagnostik. Nuklearmediziner. 2008; 31 203-208
23 Thomusch O, Sekulla C, Walls G, Fasshauer M, Dralle H. Analysis of surgery-related complications in thyroid carcinoma – a German prospective multi-centre study with 275 patients. Acta Chirurgica Austriaca. 2001; 33 194-198

Dr. med. C. Hubold

Medizinische Klinik 1
UKSH Campus Lübeck

Ratzeburger Allee 160

23538 Lübeck

Email: Christian.hubold@uk-sh.de